Interleukin-13 receptor as a unique target for anti-glioblastoma therapy

International Journal of Cancer

Volumn 92, Issue 2, 2001, Pages 168-175

  Husain, Syed R ^a   Joshi, Bharat H ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Glioblastoma; IL 13 toxin; In vivo tumor model; Interleukin 13 receptor; Tumor regression

Indexed keywords

CHIMERIC PROTEIN; IMMUNOTOXIN; INTERLEUKIN 13 RECEPTOR; PSEUDOMONAS EXOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL LINE; CLINICAL TRIAL; CLONOGENIC ASSAY; CYTOTOXICITY; DOSE RESPONSE; DRUG TARGETING; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; BRAIN NEOPLASMS; CELL DIVISION; EXOTOXINS; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; KINETICS; MICE; MICE, NUDE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035871986     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N     Document Type: Article

References (36)

1. Immunology of malignant astrocytomas
2. Brain tumors
3. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy
4. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
5. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
6. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal growth-factor receptor in patients with advanced malignant glioma
7. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin
8. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4
9. Receptors for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein
10. Interleukin-13 receptor α chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas
11. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A
12. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes
13. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses
14. Interleukin-13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin-4 receptor chain
15. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin-13
16. The attractions of proteins for small molecules and ions
17. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells
18. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin
19. Combined effects of angiostatin and ionizing radiation in antitumor therapy
20. Interleukin-4 receptor directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model
21. Novel anti-brain tumor cytotoxins specific for cancer cells
22. Interleukin-13 fusion cytotoxin as a potent targeted drug for AIDS-Kaposi's sarcoma xenograft
23. Pharmacokinetics and antitumor activity of a bivalent disulphide-stabilized Fv immunotoxin with improved antigen binding to erbB2
24. Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites
25. A phase I study of an anti-CD22-deglycosylated Ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
26. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma
27. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
28. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
29. Treatment of advanced solid tumors with immunotoxin LMB-1:An antibody linked to Pseudomonas exotoxin
30. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
31. 389IL-2) in lymphomas expressing the receptor for interleukin-2
32. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors
33. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma
34. Receptor for interleukin 13: Interaction with interleukin 4 by a mechanism that does not involve the common γ subunit of interleukins 2, 4, 7 and 15 receptor
35. Regulation of interleukin-13 receptor constituents on mature human B lymphocytes